MRI功能成像联合血清学对鉴别前列腺病变性质的临床意义

doi:10.3760/cma.j.issn.1007-1245.2024.06.019

国际医药卫生导报 ›› 2024, Vol. 30 ›› Issue (6): 973-977.DOI: 10.3760/cma.j.issn.1007-1245.2024.06.019

MRI功能成像联合血清学对鉴别前列腺病变性质的临床意义

刘涛张孝孝王敏旋

延安市人民医院CT诊断科，延安　716000

收稿日期:2023-12-11 出版日期:2024-03-01 发布日期:2024-03-29
通讯作者: 王敏旋，Email：18729119362@163.com
基金资助:
陕西省卫生计生科研基金（2016D070）

Clinical significance of MRI functional imaging combined with serology in distinguishing the nature of prostate lesions

Liu Tao, Zhang Xiaoxiao, Wang Minxuan

CT Diagnosis Department, Yan'an People's Hospital, Yan'an 716000, China

Received:2023-12-11 Online:2024-03-01 Published:2024-03-29
Contact: Wang Minxuan, Email: 18729119362@163.com
Supported by:
Health and Family Planning Research Fund of Shaanxi Province (2016D070)

摘要/Abstract

摘要：

目的　探讨MRI功能成像联合血清学对鉴别前列腺病变性质的临床意义。方法　回顾性选取2021年7月至2023年7月延安市人民医院收治的疑似前列腺癌（PCa）患者120例，均为男性，均行3.0T MRI常规扫描、弥散加权成像（DWI）扫描、磁共振波谱（MRS）成像扫描及病理检查。根据病理结果，将患者分为PCa组（53例）及良性组（67例）。PCa组年龄（63.19±4.72）岁，良性组年龄（61.75±4.54）岁。比较两组血清游离前列腺特异性抗原（fPSA）水平、总前列腺特异性抗原（tPSA）水平、MRI功能成像结果、病理结果及不同检查方式的诊断效能。采用独立样本t检验和χ²检验。结果　PCa组血清fPSA、tPSA水平均高于良性组（均P<0.05）；MRI常规扫描诊断灵敏度为69.81%（37/53）、特异度为83.58%（56/67）、准确率为77.50%（93/120），DWI诊断灵敏度为75.47%（40/53）、特异度为88.06%（59/67）、准确率为82.50%（99/120），MRS诊断灵敏度为73.58%（39/53）、特异度为86.57%（58/67）、准确率为80.83%（97/120），血清学诊断灵敏度为71.70%（38/53）、特异度为86.57%（58/67）、准确率为80.00%（96/120），联合诊断灵敏度为94.34%（50/53）、特异度为83.58%（56/67）、准确率为88.33%（106/120）；联合诊断灵敏度、阳性预测值均高于MRI功能成像、血清学单独应用，漏诊率低于MRI功能成像、血清学单独应用（均P<0.05）。结论　MRI功能成像联合血清学对PCa具有一定诊断价值，可作为临床鉴别前列腺病变性质的有效检查方式。

关键词:

前列腺病变, MRI功能成像, 游离前列腺特异性抗原, 总前列腺特异性抗原

Abstract:

Objective　To explore the clinical significance of MRI functional imaging combined with serology in distinguishing the nature of prostate lesions. Methods　A retrospective study was conducted on 120 suspected prostate cancer (PCa) patients admitted to Yan'an People's Hospital from July 2021 to July 2023, all male. All patients underwent routine 3.0T MRI scan, diffusion-weighted imaging (DWI), magnetic resonance spectroscopy (MRS), and pathological examination. Based on the pathological results, the patients were divided into a PCa group (53 cases) and a benign group (67 cases). The age of the PCa group was (63.19±4.72) years old, while the age of the benign group was (61.75±4.54) years old. Serum free prostate-specific antigen (fPSA) levels, total prostate-specific antigen (tPSA) levels, MRI functional imaging results, pathological results, and diagnostic efficacies of different examination methods were compared between the two groups. Independent sample t test and χ² test were used. Results　The serum levels of fPSA and tPSA in the PCa group were higher than those in the benign group (both P<0.05). The diagnostic sensitivity of routine MRI scanning was 69.81% (37/53), the specificity was 83.58% (56/67), and the accuracy was 77.50% (93/120). The diagnostic sensitivity of DWI was 75.47% (40/53), the specificity was 88.06% (59/67), and the accuracy was 82.50% (99/120). The diagnostic sensitivity of MRS was 73.58% (39/53), the specificity was 86.57% (58/67), and the accuracy was 80.83% (97/120). The diagnostic sensitivity of serology was 71.70% (38/53), the specificity was 86.57% (58/67), and the accuracy was 80.00% (96/120). The diagnostic sensitivity of their combination was 94.34% (50/53), the specificity was 83.58% (56/67), and the accuracy was 88.33% (106/120). The sensitivity and positive predictive value of combined diagnosis were higher than those of functional MRI imaging and serology alone, and the missed diagnosis rate was lower than that of functional MRI imaging and serology alone (all P<0.05). Conclusion　MRI functional imaging combined with serology has certain diagnostic value for PCa and can serve as an effective diagnostic method for distinguishing the nature of prostate lesions in clinical practice.

Key words:

Prostate lesions, MRI functional imaging, Free prostate specific antigen, Total prostate specific antigen

刘涛张孝孝王敏旋.

MRI功能成像联合血清学对鉴别前列腺病变性质的临床意义 [J]. 国际医药卫生导报, 2024, 30(6): 973-977.

Liu Tao, Zhang Xiaoxiao, Wang Minxuan.

Clinical significance of MRI functional imaging combined with serology in distinguishing the nature of prostate lesions [J]. International Medicine and Health Guidance News, 2024, 30(6): 973-977.

参考文献

[1] Sekhoacha M, Riet K, Motloung P, et al. Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches[J]. Molecules, 2022, 27(17):5730. DOI: 10.3390/molecules27175730.
[2] 秦丽霞,李明,贡强君,等.Notch1信号通路通过上调P15、P21、P57抑制前列腺癌细胞增殖[J].重庆医学,2023,52(12):1789-1794,1799.DOI:10.3969/j.issn.1671-8348. 2023.12.005.
[3] Vietri MT, D'Elia G, Caliendo G, et al. Hereditary prostate cancer: genes related, target therapy and prevention[J]. Int J Mol Sci, 2021, 22(7):3753. DOI: 10.3390/ijms22073753.
[4] Gandaglia G, Leni R, Bray F, et al. Epidemiology and prevention of prostate cancer[J]. Eur Urol Oncol, 2021, 4(6):877-892. DOI: 10.1016/j.euo.2021.09.006.
[5] 袁挺龙.MRI不同功能成像技术诊断子宫内膜癌的价值[J].中国妇幼保健,2021,36(6):1440-1442.DOI:10.19829/j.zgfybj.issn.1001-4411.2021.06.071.
[6] Hu L, Wei L, Wang S, et al. Better lesion conspicuity translates into improved prostate cancer detection: comparison of non-parallel-transmission-zoomed-DWI with conventional-DWI[J]. Abdom Radiol (NY), 2021, 46(12):5659-5668. DOI: 10.1007/s00261-021-03268-5.
[7] 刘凤玲,张桐硕,祝峰,等.基于分位数回归建立tPSA、fPSA、fPSA/tPSA的年龄特异性参考区间[J].临床检验杂志,2021,39(1):65-68.DOI:10.13602/j.cnki.jcls.2021.01.15.
[8] Remmers S, Bangma CH, Godtman RA, et al. Relationship between baseline prostate-specific antigen on cancer detection and prostate cancer death: long-term follow-up from the European randomized study of screening for prostate cancer[J]. Eur Urol, 2023, 84(5):503-509. DOI: 10.1016/j.eururo.2023.03.031.
[9] 中国抗癌协会泌尿肿瘤专业委员会.中国去势抵抗性前列腺癌诊治专家共识[J].中华外科杂志,2016,54(7):481-484.DOI:10.3760/cma.j.issn.0529-5815.2016.07.001.
[10] Turkbey B, Rosenkrantz AB, Haider MA, et al. Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2[J]. Eur Urol, 2019, 76(3):340-351. DOI: 10.1016/j.eururo.2019.02.033.
[11] 王蕾,黄耿,叶志华,等.miR-6893-5p对前列腺癌LNCaP细胞增殖和迁移的抑制作用及机制研究[J].国际医药卫生导报,2021,27(15):2248-2251.DOI:10.3760/cma.j.issn.1007-1245.2021.15.007.
[12] Lopci E, Lazzeri M, Colombo P, et al. Diagnostic performance and clinical impact of PSMA PET/CT versus mpMRI in patients with a high suspicion of prostate cancer and previously negative biopsy: a prospective trial (PROSPET-BX)[J]. Urol Int, 2023, 107(5):433-439. DOI: 10.1159/000528720.
[13] 朱琳,马青松,陈冰,等.经直肠超声引导下前列腺细针穿刺中液基薄层细胞学及免疫细胞化学诊断前列腺癌的应用价值[J].现代肿瘤医学,2022,30(23):4251-4254.DOI:10.3969/j.issn.1672-4992.2022.23.006.
[14] 赵洁,王红,薛力.血清PSA水平下降速率联合改良PI-RADS评分在鉴别前列腺良性疾病与前列腺癌中的价值[J].现代泌尿外科杂志,2020,25(1):32-35.DOI:10.3969/j.issn.1009-8291.2020.01.008.
[15] Liu X, Zhang Y, Duan H, et al. Risk-stratified multi-round PSA screening for prostate cancer integrating the screening reference level and subgroup-specific progression indicators[J]. Eur J Med Res, 2023, 28(1):257. DOI: 10.1186/s40001-023-01228-x.
[16] 王丽华,范璐璐,任妍.白蛋白球蛋白比值(AGR)、PSA联合Gleason评分对局限性前列腺癌患者预后的预测价值分析[J].实用癌症杂志,2023,38(6):1022-1026.DOI:10.3969/j.issn.1001-5930.2023.06.040.
[17] Omri N, Kamil M, Alexander K, et al. Association between PSA density and pathologically significant prostate cancer: the impact of prostate volume[J]. Prostate, 2020, 80(16):1444-1449. DOI: 10.1002/pros.24078.
[18] 鄂少龙,张旖骁,吴斌.MRI阴性且PSA异常男性患者前列腺穿刺阳性的风险因素分析[J].中华男科学杂志,2021,27(10):886-891.DOI:10.13263/j.cnki.nja.2021.10.004.
[19] 孙欣,殷锋彦,罗晓辉,等.经尿道前列腺1470nm激光剜除术治疗大体积前列腺疗效及对患者尿流动力学和血清T-PSA、F-PSA水平的影响[J].贵州医药,2023,47(10):1540-1541.DOI:10.3969/j.issn.1000-744X.2023.10.011.
[20] Sun KX, Yan CL, Li ZY, et al. [Clinical value of serum isoform [-2] proprostate-specific antigen and its derivatives in predicting aggressive prostate cancer][J]. Beijing Da Xue Xue Bao Yi Xue Ban, 2020, 52(2):234-239. DOI: 10.19723/j.issn.1671-167X.2020.02.007.
[21] 张苏波,李绍东.基于PI-RADS v2评分联合PSAD、fPSA/tPSA在PSA灰区前列腺癌的应用研究[J].临床放射学杂志,2021,40(1):105-109.DOI:10.13437/j.cnki.jcr.2021.01.025.
[22] 阴志琦,张靖宇.血清铁蛋白联合前列腺特异性抗原检测对前列腺癌的诊断价值[J].癌症进展,2020,18(6):593-596.DOI:10.11877/j.issn.1672-1535.2020.18.06.15.
[23] 陈晓华,郭作梁,马兴灿,等.3.0T磁共振多种功能成像技术在前列腺癌诊断中的应用价值研究[J].中国CT和MRI杂志,2021,19(1):144-146.DOI:10.3969/j.issn.1672-5131. 2021.01.049.
[24] 吴慧,吴静,蔚纳,等.单指数、双指数、拉伸指数DWI模型鉴别前列腺癌与基质型前列腺增生的价值研究[J].磁共振成像,2020,11(7):546-551.DOI:10.12015/issn.1674-8034. 2020.07.014.
[25] 陆健美,葛建钢,王静,等.联合应用3.0T磁共振T2WI、DWI及DCE-MRI成像诊断前列腺癌[J].实用肿瘤杂志,2020,35(4):355-359.DOI:10.13267/j.cnki.syzlzz.2020.04.014.
[26] 陈志强,张丹,王卓,等.DISCO和MUSE-DWI联合前列腺特异性抗原密度在前列腺癌的诊断及危险分层中的价值[J].中华医学杂志,2023,103(19):1461-1468.DOI:10.3760/cma.j.cn112137-20221018-02176.
[27] 张海青,张子林.多模态功能磁共振成像对前列腺良恶性疾病的诊断价值[J].安徽医学,2021,42(3):277-280.DOI:10.3969/j.issn.1000-0399.2021.03.011.
[28] 毛滢,李学坤.多模态磁共振成像在前列腺外周带癌诊断中的应用价值分析[J].中国CT和MRI杂志,2023,21(10):139-141.DOI:10.3969/j.issn.1672-5131.2023.10.043.
[29] 张杰,郭莹,霍阿伟,等.DCE-MRI、表观扩散系数对前列腺癌分级诊断的应用比较[J].河北医科大学学报,2021,42(4):444-447,453.DOI:10.3969/j.issn.1007-3205.2021.04.016.
[30] 叶德刚,赵亮亮,马平.前列腺癌多参数磁共振成像特征及临床诊断价值分析[J].中国医师杂志,2022,24(1):64-68.DOI:10.3760/cma.j.cn431274-20210122-00092.

MRI功能成像联合血清学对鉴别前列腺病变性质的临床意义

Clinical significance of MRI functional imaging combined with serology in distinguishing the nature of prostate lesions

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics